Podcasts

AUDIO: An interview with Dr. Thomas Insel, part II


 

References

HOLLYWOOD, FLA. – In the United States, rates of mental illness continue to increase while rates of cure do not. That’s according to a recent report on the global disease burden published in JAMA (2013;310:591-608).

For that reason, leaders in the mental health field such as Dr. Thomas Insel, director of the National Institute of Mental Health, and who is both a psychiatrist and a neuroscientist, are supporting President Barack Obama’s BRAIN Initiative. The 12-year vision with a projected $4.5 billion price tag that goal has among its aims. The hope is that the initiative will help determine biomarkers aimed at finding effective cures for a variety of mental illnesses.

Dr. Thomas Insel

After Dr. Insel spoke at the plenary session of this year’s annual meeting of the American Society of Clinical Psychopharmacology, formerly known as the New Clinical Drug Evaluation Unit meeting, he sat for an interview with this news organization.

This is part II of that interview. In this segment, Dr. Insel discusses how the BRAIN Initiative could change practice for psychiatrists and other mental health professionals. Dr. Insel also describes how he thinks the collaboration of many scientists will aid in the quest to understand the biology of the brain. In addition, he describes how funding in this new era will be determined for those interested in applying for research grants.

wmcknight@frontlinemedcom.com

On Twitter @whitneymcknight

Recommended Reading

Letizia Leocani, MD, PhD
MDedge Neurology
FDA approves drug for opioid-induced constipation in chronic noncancer pain population
MDedge Neurology
AEDs perform largely the same in reducing secondary generalized tonic-clonic seizures
MDedge Neurology
Managing Your Practice: What is your practice worth?
MDedge Neurology
Phase II RADIANCE study results demonstrate efficacy of RPC1036 in MS
MDedge Neurology
Interferon beta-1a, glatiramer acetate prove cost effective for long-term MS treatment
MDedge Neurology
VIDEO: Novel sphingosine 1-phosphate 1 receptor modulator has promising safety results
MDedge Neurology
IOM calls for pay for end-of-life planning
MDedge Neurology
AMA calls on vendors, feds to improve usability of EHRs
MDedge Neurology
Trial probes mechanism of THC-CBD improvement of multiple sclerosis spasticity
MDedge Neurology